Feedback / Questions
Yutuo (zimberelimab) - Arcus Biosci, Gilead
domvanalimab (AB154) - Arcus Biosci, Gilead
https://investors.arcusbio.com/investors-and-media/press-releases/press-release-details/2025/Arcus-Provides-Update-on-Phase-3-STAR-221-Study-and-Concentrates-Its-RD-Investment-on-Casdatifan-and-Emerging-Inflammation-and-Immunology-Portfolio/default.aspx
Dec 12, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next